Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
Completed · Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk women. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing breast cancer in premenopausal women who are at risk of developing cancer.
Key facts
- Study ID
- NCT00056082
- Run by
- University of Kansas Medical Center
- People needed
- 110
- Starts
- 2003-01-01
- Expected to finish
- 2013-07-01
- Last updated by the study team
- 2017-02-15
Who can join
Age: 18 and older, up to 55. Sex: female. Healthy volunteers: accepted.
Where it is running
- Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital — Chicago, Illinois, United States
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center — Kansas City, Kansas, United States
- Oklahoma University Medical Center — Oklahoma City, Oklahoma, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.